Evidence map›Paper›PMID 28261102›Full record

ArticleFrontiers in pharmacology2017

Genetic and Pharmacological Inhibition of p38α Improves Locomotor Recovery after Spinal Cord Injury.

Hiroki Umezawa, Yusuke Naito, Kensuke Tanaka, Kento Yoshioka, Kenichi Suzuki, Tatsuhiko Sudo, Masahiko Hagihara, Masahiko Hatano, Koichiro Tatsumi, Yoshitoshi Kasuya

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Functions of p38 MAP Kinases in the Central Nervous System.Frontiers in molecular neuroscience · 2020
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Hiroki UmezawaDepartment of Respirology, Graduate School of Medicine, Chiba UniversityChiba, Japan; Department of Biochemistry and Molecular Pharmacology, Graduate School of Medicine, Chiba UniversityChiba, Japan; Department of Biomedical Science, Graduate School of Medicine, Chiba UniversityChiba, Japan.
Yusuke NaitoDepartment of Respirology, Graduate School of Medicine, Chiba UniversityChiba, Japan; Department of Biochemistry and Molecular Pharmacology, Graduate School of Medicine, Chiba UniversityChiba, Japan; Department of Biomedical Science, Graduate School of Medicine, Chiba UniversityChiba, Japan.
Kensuke TanakaDepartment of Respirology, Graduate School of Medicine, Chiba UniversityChiba, Japan; Department of Biochemistry and Molecular Pharmacology, Graduate School of Medicine, Chiba UniversityChiba, Japan.
Kento YoshiokaDepartment of Biochemistry and Molecular Pharmacology, Graduate School of Medicine, Chiba UniversityChiba, Japan; Department of Biomedical Science, Graduate School of Medicine, Chiba UniversityChiba, Japan.
Kenichi SuzukiDepartment of Respirology, Graduate School of Medicine, Chiba UniversityChiba, Japan; Department of Biomedical Science, Graduate School of Medicine, Chiba UniversityChiba, Japan.
Tatsuhiko SudoChemical Biology Core Facility and Antibiotics Laboratory, RIKEN Advanced Science Institute Saitama, Japan.
Masahiko HagiharaCorporate Research & Development, Ube Industries, Ltd Ube, Japan.
Masahiko HatanoDepartment of Biomedical Science, Graduate School of Medicine, Chiba University Chiba, Japan.
Koichiro TatsumiDepartment of Respirology, Graduate School of Medicine, Chiba University Chiba, Japan.
Yoshitoshi KasuyaDepartment of Biochemistry and Molecular Pharmacology, Graduate School of Medicine, Chiba UniversityChiba, Japan; Department of Biomedical Science, Graduate School of Medicine, Chiba UniversityChiba, Japan.
Chiba University · JPRIKEN Advanced Science Institute · JPUbe (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the mitogen-activated protein kinases, p38α plays a crucial role in various inflammatory diseases and apoptosis of various types of cells. In this study, we investigated the pathophysiological roles of p38α in spinal cord injury (SCI), using a mouse model. Lateral hemisection at T9 of the SC was performed in wild type (WT) and p38α

Indexed as

p38 mitogen-activated protein kinasesrecovery of locomotor activityspinal cord injury (SCI)tissue degenerationtissue regeneration

Identifiers

PMID28261102
PMCPMC5313485
OpenAlexW2588142525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.